The $64,000 question-What is a quality-adjusted life-year worth?

Clinical Therapeutics

Volumn 28, Issue 7, 2006, Pages 1042-1043

  Rascati, Karen L ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION MAKING; DISABILITY; EDITORIAL; FINANCIAL MANAGEMENT; HEALTH CARE POLICY; PUBLIC HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; WORLD HEALTH ORGANIZATION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DATA INTERPRETATION, STATISTICAL; ENZYME INHIBITORS; GRAM-NEGATIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; MONTE CARLO METHOD; PENICILLANIC ACID; PIPERACILLIN;

EID: 33748596078     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.07.002     Document Type: Editorial

References (11)

1. Gold M., Patrick D., Torrance G., et al. Identifying and valuing outcomes. In: Gold M., Siegel J., Russell L., and Weinstein M. (Eds). Cost-Effectiveness in Health and Medicine (1996), Oxford University Press, New York, NY 82-134
2. Available at. National Institute for Clinical Excellence. Accessed June 23, 2006. http://www.nice.org
3. Eichler H., Kong S., Gerth W., et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge?. Value Health 7 (2004) 518-528
4. George B., Harris A., and Mitchell A. Cost-effectiveness analysis and the consistency of decision making: Evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 19 (2001) 1103-1109
5. Devlin N., and Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 23 (2004) 437-452
6. Schwappach D. Resource allocation, social values and the QALY: A review of the debate and empirical evidence. Health Expect. 5 (2002) 210-222
7. Gyrd-Hansen D. Willingness to pay for a QALY: Theoretical and methodological issues. Pharmacoeconomics 23 (2005) 423-432
8. Editorial. Johnson F. Einstein on willingness to pay per QALY: Is there a better way?. Med Decis Making 25 (2005) 607-608
9. O'Brien B., Gertsen K., Willan A., and Faulkner L. Is there a kink in consumers' threshold value for cost-effectiveness in health care?. Health Econ 11 (2002) 175-180
10. Hirth R., Chernew M., Miller E., et al. Willingness to pay for a quality-adjusted life year: In search of a standard. Med Decis Making 20 (2000) 332-342
11. Editorial. Buxton M. How much are health-care systems prepared to pay to produce a QALY?. Eur J Health Econ 6 (2005) 285-287